However, these cohorts enrolled patients who had predominantly low or negative PD-L1 staining (<5% PD-L1 expression on tumor-infiltrating immune cells (IC) and tumor cells (TC) per SP142) (Table 1), thereby compromising direct comparison with historical efficacy benchmarks achieved with CPI monotherapy. This evidence concerns the gene CD274 and neoplasm.